Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of TQH2929 in healthy adults
NCT06156280Phase 1Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TQH2929 in psoriasis (6 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Adverse events rate at Day 113, Serious adverse events rate at Day 113 and 2 more. Started Nov 2023; status: completed.
02
Drugs
TQH2929
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT06156280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156280.